Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Madurella mycetomatis Is Highly Susceptible to Ravuconazole
PLoS Neglected Tropical Diseases, Volume 8, No. 6, Article e2942, Year 2014
Notification
URL copied to clipboard!
Description
The current treatment of eumycetoma utilizing ketoconazole is unsatisfactory because of high recurrence rates, which often leads to complications and unnecessary amputations, and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum triazole currently being developed for the treatment of Chagas disease. E1224 is a prodrug that is rapidly converted to ravuconazole. Plasma levels of E1224 are low and transient, and its therapeutically active moiety, ravuconazole is therapeutically active. In the present study, the in vitro activity of ravuconazole against Madurella mycetomatis, the most common etiologic agent of eumycetoma, was evaluated and compared to that of ketoconazole and itraconazole. Ravuconazole showed excellent activity with MICs ranging between ≤0.002 and 0.031 μg/ml, which were significantly lower than the MICs reported for ketoconazole and itraconazole. On the basis of our findings, E1224 with its resultant active moiety, ravuconazole, could be an effective and affordable therapeutic option for the treatment of eumycetoma. © 2014 Ahmed et al.
Authors & Co-Authors
Ahmed, Sarah A.
Sudan, Khartoum
Khartoum University
Netherlands, Utrecht
Westerdijk Fungal Biodiversity Institute - Knaw
Netherlands, Amsterdam
Institute for Biodiversity and Ecosystem Dynamics - Amsterdam
Kloezen, Wendy
Netherlands, Rotterdam
Erasmus Mc
Duncanson, Frederick
United States, Nutley
Eisai Inc.
Zijlstra, Eduard Evert
Netherlands, Rotterdam
Rotterdam Centre for Tropical Medicine
de Hoog, Gerrits Sybren
Netherlands, Utrecht
Westerdijk Fungal Biodiversity Institute - Knaw
Netherlands, Amsterdam
Institute for Biodiversity and Ecosystem Dynamics - Amsterdam
China, Beijing
Peking University Health Science Center
China, Guangzhou
Sun Yat-sen University
China, Shanghai
Changzheng Hospital
Brazil, Curitiba
Universidade Federal do Parana
Saudi Arabia, Jeddah
King Abdulaziz University
Hassan Fahal, Ahmed Hassan
Sudan, Khartoum
Khartoum University
van de Sande, Wendy W.J.
Netherlands, Rotterdam
Erasmus Mc
Statistics
Citations: 40
Authors: 7
Affiliations: 11
Identifiers
Doi:
10.1371/journal.pntd.0002942
ISSN:
19352727
e-ISSN:
19352735